Ovarian Cancer
GYOEDU Resident: Ovarian Cancer Surveillance and Recurrences
PAOLA-1 (2023 Update): Final Overall Survival Results — Olaparib plus Bevacizumab First-Line Maintenance in Ovarian Cancer
Olaparib combined with bevacizumab provided a OS benefit for HRD-positive ovarian cancer patients.
HIPEC in ovarian cancer
Korean HIPEC Trial: HIPEC After Primary or Interval Cytoreductive Surgery in Ovarian Cancer
The addition of HIPEC after interval cytoreductive surgery following neoadjuvant chemotherapy provided significant improvements in PFS and OS.
Mucinous Ovarian Carcinoma
mEOC/GOG-0241: Oxaliplatin-Capecitabine vs. Carboplatin-Paclitaxel in Mucinous Epithelial Ovarian Cancer
Neither oxaliplatin-capecitabine nor bevacizumab significantly improved OS or PFS compared to paclitaxel-carboplatin in advanced-stage mucinous ovarian cancer.